The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Norepinephrine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of PIK3CG protein]; [Norepinephrine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP]
CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of CLDN1 mRNA] Tretinoin results in increased expression of CLDN1 mRNA; Tretinoin results in increased expression of CLDN1 protein
Tretinoin results in increased expression of CLDN4 mRNA; Tretinoin results in increased expression of CLDN4 protein CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of CLDN4 mRNA]
CYP26A1 protein results in increased degradation of Tretinoin CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of CLDN1 mRNA]; CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of CLDN4 mRNA]; CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of OCLN mRNA]; CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of TJP1 mRNA]
CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of OCLN mRNA] Tretinoin results in increased expression of OCLN mRNA; Tretinoin results in increased expression of OCLN protein
Tretinoin results in increased expression of TJP1 mRNA; Tretinoin results in increased expression of TJP1 protein CYP26A1 protein inhibits the reaction [Tretinoin results in increased expression of TJP1 mRNA]
[Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Sarin results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Soman results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [VX results in decreased activity of ACHE protein]
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of CCL17 promoter
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of CCL2 promoter
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of IL31RA promoter
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of TSLP promoter
[Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate; Yohimbine inhibits the reaction [[Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; Yohimbine inhibits the reaction [Clonidine results in increased activity of PIK3CG protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein]; Yohimbine inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein]
Clonidine results in increased activity of PIK3CG protein [Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate; Yohimbine inhibits the reaction [[Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; Yohimbine inhibits the reaction [Clonidine results in increased activity of PIK3CG protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein]; Yohimbine inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein]
[Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate; Yohimbine inhibits the reaction [[Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; Yohimbine inhibits the reaction [Clonidine results in increased activity of PIK3CG protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein]; Yohimbine inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Colforsin co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Colforsin co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; [Colforsin co-treated with INS protein] results in increased phosphorylation of MAPK1 protein; [Colforsin co-treated with INS protein] results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Colforsin co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; [Colforsin co-treated with INS protein] results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Colforsin co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; [Colforsin co-treated with INS protein] results in increased phosphorylation of MAPK3 protein
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; Glutathione inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; U 0126 inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]
Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]
Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]
Atenolol inhibits the reaction [Isoproterenol results in increased activity of REN protein]; Pindolol inhibits the reaction [Isoproterenol results in increased activity of REN protein]; Propranolol inhibits the reaction [Isoproterenol results in increased activity of REN protein]; xibenolol inhibits the reaction [Isoproterenol results in increased activity of REN protein]
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of CCL17 promoter
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of CCL2 promoter
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of IL31RA promoter
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL17 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of CCL2 mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of IL31RA mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]
[Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] inhibits the reaction [[IL4 protein co-treated with IL13 protein co-treated with IL31 protein] results in increased expression of TSLP mRNA]; [Cannabidiol co-treated with Luteolin co-treated with 3,3',4,5'-tetrahydroxystilbene] results in increased methylation of TSLP promoter
CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of ACTA2 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein] ochratoxin A results in increased expression of ACTA2 mRNA; ochratoxin A results in increased expression of ACTA2 protein
ochratoxin A results in increased expression of TGFB1 mRNA; ochratoxin A results in increased expression of TGFB1 protein CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of TGFB1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein] ochratoxin A results in increased expression of GSDMD mRNA; ochratoxin A results in increased expression of GSDMD protein
CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL18 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL1B mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein] ochratoxin A results in increased expression of IL1B mRNA; ochratoxin A results in increased expression of IL1B protein
N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of CASP1 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of VIM protein] ochratoxin A results in increased expression of NLRP3 mRNA; ochratoxin A results in increased expression of NLRP3 protein
ochratoxin A results in increased expression of PYCARD mRNA; ochratoxin A results in increased expression of PYCARD protein N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD protein]
CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of VIM protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of VIM protein] ochratoxin A results in increased expression of VIM mRNA; ochratoxin A results in increased expression of VIM protein
Phenylephrine binds to and results in increased activity of ADRA1A protein; silodosin inhibits the reaction [Phenylephrine binds to and results in increased activity of ADRA1A protein]
BMY 7378 inhibits the reaction [Phenylephrine binds to and results in increased activity of ADRA1D protein]; naftopidil inhibits the reaction [Phenylephrine binds to and results in increased activity of ADRA1D protein]; Phenylephrine binds to and results in increased activity of ADRA1D protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; [Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK1 protein; [Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; [Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; [Tetradecanoylphorbol Acetate co-treated with INS protein] results in increased phosphorylation of MAPK3 protein
Tetradecanoylphorbol Acetate promotes the reaction [Monensin affects the localization of SLC6A9 protein] Tetradecanoylphorbol Acetate affects the localization of SLC6A9 protein
Propranolol inhibits the reaction [Isoproterenol results in increased activity of REN protein] Propranolol results in decreased activity of REN protein
[salicylamide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to prochloraz; [salicylamide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to Tetrachlorodibenzodioxin
Ditiocarb inhibits the reaction [CYP2E1 protein affects the metabolism of Toluene]; Fomepizole inhibits the reaction [CYP2E1 protein affects the metabolism of Toluene]
[Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Sarin results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Soman results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [VX results in decreased activity of ACHE protein]
Yohimbine inhibits the reaction [[Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; Yohimbine inhibits the reaction [Clonidine results in increased activity of PIK3CG protein]